Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors
Journal
Diabetologia
Journal Volume
64
Journal Issue
9
Date Issued
2021-09
Author(s)
Abstract
The safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP1RAs) and dipeptidyl peptidase-4 inhibitors (DPP4is) in major cardiovascular adverse events were previously examined in cardiovascular outcome trials. However, the effects of these drugs on adverse limb outcomes were poorly examined. This study aimed to determine the real-world outcomes of patients with diabetes mellitus receiving GLP1RAs as compared with those receiving DPP4is in terms of major adverse cardiovascular and limb events.
Subjects
Diabetes; Dipeptidyl peptidase-4 inhibitors; Glucagon-like peptide-1 receptor agonist; Major adverse cardiovascular events; Major adverse limb events
SDGs
Other Subjects
2,4 thiazolidinedione derivative; acetylsalicylic acid; alpha glucosidase inhibitor; anticoagulant agent; antidiabetic agent; beta adrenergic receptor blocking agent; calcium channel blocking agent; cilostazol; clopidogrel; cyclooxygenase 2 inhibitor; dig
Type
journal article